Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

Clinical Pharmacokinetics

Volumn 43, Issue 13, 2004, Pages 925-942

  Moise Broder, Pamela A ^a   Forrest, Alan ^a,b   Birmingham, Mary C ^a   Schentag, Jerome J ^a,b  

^a CPL Associates LLC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; NETILMICIN; OXACILLIN; RIFAMPICIN; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; COMORBIDITY; DRUG EFFICACY; FEMALE; HUMAN; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; TEACHING HOSPITAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 7444254040     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443130-00005     Document Type: Article

References (74)

1. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37 (5): 1073-81
2. Highet VS, Forrest A, Ballow CH, et al. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 1999; 43 Suppl. A: 55-63
3. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 1991; 25 (10): 1050-7
4. Goss TF, Forrest A, Nix DE, et al. Mathematical examination of dual individualization principles (K): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994; 28 (7-8): 863-8
5. Schentag JJ. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. J Chemother 2002; 14 Suppl. 2: 13-21
6. Schentag JJ. Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. Crit Care Med 2001; 29 (4 Suppl.): N100-7
7. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates (Pt 2): human trials. Ann Pharmacother 2003; 37 (10): 1478-88
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26(1): 1-10
9. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there [published erratum appears in Clin Infect Dis 1994 Aug; 19 (2): 379]. Clin Infect Dis 1994; 18 (4): 544-6
10. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there [published erratum appears in Clin Infect Dis 1994 Aug; 19 (2): 379]. Clin Infect Dis 1994; 18 (4): 544-6
11. Kralovicova K, Spanik S, Halko J, et al. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients? J Chemother 1997; 9 (6): 420-6
12. Burnie J, Matthews R, Jiman-Fatami A, et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 2000; 31 (3): 684-9
13. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides [published erratum appears in J Clin Microbiol 1998 Jul; 36 (7): 2167]. J Clin Microbiol 1998; 36 (4): 1020-7
14. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides [published erratum appears in J Clin Microbiol 1998 Jul; 36 (7): 2167]. J Clin Microbiol 1998; 36 (4): 1020-7
15. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1990 to May 1999. Issued June 1999. Am J Infect Control 1999; 27: 520-32
16. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339 (8): 520-32
17. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992; 13 (10): 582-6
18. Atkinson BA, Lorian V. Antimicrobial agent susceptibility patterns of bacteria in hospitals from 1971 to 1982. J Clin Microbiol 1984; 20 (4): 791-6
19. Ploy MC, Grelaud C, Martin C, et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [letter]. Lancet 1998; 351 (9110): 1212
20. McManus J. Vancomycin resistant Staphylococcus reported in Hong Kong. BMJ 1999; 318 (7184): 626
21. Sieradzki K, Roberts RB, Haber SW, et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340 (7): 517-23
22. Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181 (24): 7566-70
23. Hiramatsu K, Hanaki H. Glycopeptide resistance in staphylococci. Curr Opin Infect Dis 1998; 11: 653-8
24. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [letter]. J Antimicrob Chemother 1997; 40 (1): 135-6
25. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340 (7): 493-501
26. Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5 (1): 147-9
27. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16 Suppl. 1: S31-4
28. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32 (3): 402-12
29. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46 (5): 775-84
30. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45 (9): 2460-7
31. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36 (4): 429-39
32. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36 (1): 53-9
33. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34 (11): 1481-90
34. Johnson JR. Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2003; 36 (2): 236-7
35. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44 (2): 263-73
36. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57 Suppl. 2: S4-9
37. ASHP. Correction on AUIC and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections caused by Staphylococcus aureus. Am J Health Syst Pharm 2001; 58: 78
38. Center for Drug Evaluation and Research. Evaluating clinical studies of antimicrobials in the division of anti-infective drug products. FDA draft guidance [online]. Available from URL: http://www.fda.gov/cder/guidance/ draft9al.pdf [Accessed 2004 Aug 9]
39. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13 (10): 818-29
40. Luzier A, Goss TF, Cumbo TJ, et al. Mathematical examination of dual individualization principles (III): development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime-treated patients. Ann Pharmacother 1992; 26 (11): 1358-65
41. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
42. Amsden GW, Ballow CH, Schentag JJ. Population pharmacokinetic methods to optimise antibiotic effects. Drug Invest 1993; 5: 256-68
43. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32 (6): 848-52
44. Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19 (4): 355-88
45. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28 (2): 143-60
46. Rotschafer JC, Crossley K, Zaske DE, et al. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 22 (3): 391-4
47. Healy DP, Polk RE, Garson ML, et al. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987; 31 (3): 393-7
48. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988; 43 (5): 565-70
49. Sgarabotto D, Cusinato R, Name E, et al. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand J Infect Dis 2002; 34 (2); 122-6
50. Watanakunakorn C, Guerriero JC. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 1981; 19 (6): 1089-91
51. Tuazon CU, Lin MY, Sheagren JN. In vitro activity of rifampin alone and in combination with nafcillin and vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13 (5): 759-61
52. Faville Jr RJ, Zaske DE, Kaplan EL, et al. Staphylococcus aureus endocarditis: combined therapy with vancomycin and rifampin. JAMA 1978; 240 (18): 1963-5
53. Massanari RM, Donta ST. The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis. Chest 1978; 73 (3): 371-5
54. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115(9): 674-80
55. McGrath BJ, Kang SL, Kaatz GW, et al. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob Agents Chemother 1994; 38 (9): 2034-40
56. Watanakunakorn C, Tisone JC. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1982; 22 (5): 903-5
57. Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997; 41 (11): 2497-501
58. Mouton JW, van Ogtrop ML, Andes D, et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999; 43 (10): 2473-8
59. Hyatt JM, Luzier AB, Forrest A, et al. Modeling the response of pneumonia to antimicrobial therapy. Antimicrob Agents Chemother 1997; 41 (6): 1269-74
60. Zokufa HZ, Rodvold KA, Blum RA, et al. Simulation of vancomycin peak and trough concentrations using five dosing methods in 37 patients. Pharmacotherapy 1989; 9 (1): 10-6
61. Klepser ME, Kang SL, McGrath BJ. Influence of vancomycin serum concentration on the outcome of gram-positive infections [abstract]. Program and abstracts of the American College of Clinical Pharmacy Annual Winter Meeting; 1994 Feb 6-9; San Diego
62. Garrod LP, Lambert HP, O'Grady F. Various antibacterial agents. 4th ed. London: Churchill Livingstone, 1973
63. Geraci JE. Vancomycin. Mayo Clin Proc 1977; 52 (10): 631-4
64. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150 (6 Pt 1): 1545-9
65. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29 (5): 1171-7
66. Schentag JJ. Clinical significance of antibiotic tissue penetration. Clin Pharmacokinet 1989; 16 Suppl. 1: 25-31
67. Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991; 35 (10): 1947-52
68. Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 1991; 35 (10): 1953-9
69. Matzke GR. Vancomycin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics, principles of drug monitoring. Vancouver (WA): Applied Therapeutics Inc., 1992: 15.1-15.30
70. Ackerman BH, Berg HG, Strate RG, et al. Comparison of radioimmunoassay and fluorescent polarization immunoassay for quantitative determination of vancomycin concentrations in serum. J Clin Microbiol 1983; 18 (4): 994-5
71. Zokufa HZ, Solem LD, Rodvold KA, et al. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J Burn Care Rehabil 1989; 10 (5): 425-8
72. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44 (2): 251-61
73. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36 (2): 159-68
74. Moise PA, Forrest A, Birmingham MC, et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50 (6): 1017-26